The Claim
The prevalence of anti-nuclear antibodies in patients with Graves' disease is 80%, and this prevalence is higher than in the general population but not significantly different between patients with and without Graves' orbitopathy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people diagnosed with Graves' disease, 80% have anti-nuclear antibodies. This rate is higher than in people without Graves' disease, but it does not differ significantly between those who have eye complications from the disease and those who do not.
See the scientific wording
The prevalence of anti-nuclear antibodies in patients with Graves' disease is 80%, which is higher than the general population but not significantly different between those with and without Graves' orbitopathy.
In people with Graves' disease, the immune system produces antibodies that target the cell nucleus, and this presence is linked to a shift in immune cells that reduces inflammation in the thyroid and behind the eyes, making the disease less severe without stopping the disease itself.
What the research says
1 studyStudy: Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
About 8 out of 10 people with Graves' disease have these antibodies, whether or not they have eye problems—so the antibodies are common in the disease but don't seem to cause the eye symptoms.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.